Sarah Boyce's Insider Trades & SAST Disclosures
Sarah Boyce's most recent trade in Avidity Biosciences Inc was a trade of 31,540 Common Stock done at an average price of $31.1 . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sarah Boyce.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.06 per share. | 20 Mar 2025 | 31,540 | 305,871 | - | 31.1 | 979,563 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 600 | 11,459 (0%) | 0% | 0 | Common Stock | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 06 Feb 2025 | 55 | 10,859 (0%) | 0% | 25.3 | 1,392 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 21 Jan 2025 | 5,659 | 337,411 | - | 28.6 | 161,817 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 21 Jan 2025 | 4,738 | 343,070 | - | 28.6 | 135,475 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 165,000 | 165,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 82,500 | 347,808 | - | 0 | Common Stock | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 31 Dec 2024 | 38 | 10,803 (0%) | 0% | 26.1 | 993 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.66 per share. | 18 Dec 2024 | 31,855 | 265,308 | - | 32.7 | 1,040,384 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2024 | 62,500 | 267,543 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2024 | 62,500 | 297,163 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.00 per share. | 19 Sep 2024 | 32,880 | 234,663 | - | 44.0 | 1,446,723 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 06 Aug 2024 | 28,000 | 233,043 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 43.35 per share. | 06 Aug 2024 | 28,000 | 205,043 | - | 43.4 | 1,213,822 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 28,000 | 461,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 09 Jul 2024 | 28,000 | 233,043 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2024 | 28,000 | 489,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.93 per share. | 09 Jul 2024 | 28,000 | 205,043 | - | 39.9 | 1,118,082 | Common Stock |
| Contineum Therapeutics Inc... | Sarah Boyce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Sarah Boyce | Director | 18 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| OmniAb Inc | Sarah Boyce | Director | 18 Jun 2024 | 20,000 | 0 | - | - | Restricted Stock Units | ||
| OmniAb Inc | Sarah Boyce | Director | 18 Jun 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| OmniAb Inc | Sarah Boyce | Director | 18 Jun 2024 | 20,000 | 68,381 | - | - | Common Stock | ||
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 62,500 | 205,043 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 62,500 | 174,617 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.13 per share. | 17 Jun 2024 | 32,074 | 142,543 | - | 39.1 | 1,255,040 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 12 Jun 2024 | 164,233 | 112,117 | - | 40.1 | 6,581,802 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 12 Jun 2024 | 164,233 | 276,350 | - | 1.2 | 203,649 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 164,233 | 552,782 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 100,000 | 717,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.73 per share. | 12 Jun 2024 | 100,000 | 112,117 | - | 35.7 | 3,573,020 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 12 Jun 2024 | 100,000 | 212,117 | - | 1.2 | 124,000 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 12 Jun 2024 | 35,767 | 112,117 | - | 40.1 | 1,433,484 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 12 Jun 2024 | 35,767 | 147,884 | - | 1.2 | 44,351 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 35,767 | 517,015 | - | - | Stock Option (Right to Buy) | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 10 Jun 2024 | 900 | 7,588 (0%) | 0% | 18 | 16,200 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 19.40 per share. | 10 Jun 2024 | 500 | 8,588 (0%) | 0% | 19.4 | 9,700 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 19.45 per share. | 10 Jun 2024 | 500 | 8,088 (0%) | 0% | 19.5 | 9,725 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 18.81 per share. | 10 Jun 2024 | 495 | 9,083 (0%) | 0% | 18.8 | 9,311 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 10 Jun 2024 | 75 | 6,605 (0%) | 0% | 15.2 | 1,141 | Common Stock | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 10 Jun 2024 | 65 | 6,688 (0%) | 0% | 15.3 | 992 | Common Stock | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 10 Jun 2024 | 17 | 6,622 (0%) | 0% | 14.8 | 251 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 04 Jun 2024 | 28,000 | 140,117 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2024 | 28,000 | 817,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.42 per share. | 04 Jun 2024 | 28,000 | 112,117 | - | 27.4 | 767,780 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 07 May 2024 | 28,000 | 140,117 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2024 | 28,000 | 845,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.54 per share. | 07 May 2024 | 28,000 | 112,117 | - | 25.5 | 715,050 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Grant, award, or other acquisition of securities at price $ 14.05 per share. | 01 May 2024 | 1,210 | 6,390 (0%) | 0% | 14.1 | 17,001 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | 01 May 2024 | 139 | 6,529 (0%) | 0% | 14.3 | 1,987 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 02 Apr 2024 | 28,000 | 140,117 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2024 | 28,000 | 873,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.25 per share. | 02 Apr 2024 | 28,000 | 112,117 | - | 26.2 | 734,919 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 08 Mar 2024 | 84,000 | 196,117 | - | 1.2 | 104,160 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.39 per share. | 08 Mar 2024 | 84,000 | 112,117 | - | 21.4 | 1,796,710 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 84,000 | 929,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 28,000 | 901,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.63 per share. | 08 Mar 2024 | 28,000 | 112,117 | - | 22.6 | 633,682 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 08 Mar 2024 | 28,000 | 140,117 | - | 1.2 | 34,720 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 01 Mar 2024 | 84,000 | 196,117 | - | 1.2 | 104,160 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 01 Mar 2024 | 84,000 | 112,117 | - | 20.1 | 1,691,306 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 84,000 | 1,013,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2024 | 62,500 | 67,209 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.13 per share. | 20 Jan 2024 | 5,092 | 44,008 | - | 10.1 | 51,582 | Common Stock |
| Old Point Financial Corp. | Golden Boyce Sarah | Director | Purchase of securities on an exchange or from another person at price $ 16.95 per share. | 05 Dec 2023 | 59 | 4,766 (0%) | 0% | 16.9 | 1,000 | Common Stock |
| OmniAb Inc | Sarah Boyce | Director | 23 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| OmniAb Inc | Sarah Boyce | Director | 23 Jun 2023 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 12 Jun 2023 | 100 | 4,369 (0%) | 0% | 16 | 1,600 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.09 per share. | 12 Jun 2023 | 100 | 4,469 (0%) | 0% | 16.1 | 1,609 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.20 per share. | 08 Jun 2023 | 100 | 4,069 (0%) | 0% | 16.2 | 1,620 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 15.55 per share. | 08 Jun 2023 | 100 | 4,269 (0%) | 0% | 15.6 | 1,555 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.34 per share. | 08 Jun 2023 | 100 | 4,169 (0%) | 0% | 16.3 | 1,634 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.49 per share. | 06 Jun 2023 | 100 | 3,969 (0%) | 0% | 16.5 | 1,649 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.43 per share. | 05 Jun 2023 | 100 | 3,869 (0%) | 0% | 16.4 | 1,643 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.61 per share. | 02 Jun 2023 | 100 | 3,769 (0%) | 0% | 16.6 | 1,661 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.38 per share. | 01 Jun 2023 | 200 | 3,569 (0%) | 0% | 16.4 | 3,277 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.40 per share. | 01 Jun 2023 | 100 | 3,669 (0%) | 0% | 16.4 | 1,640 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 18.50 per share. | 24 May 2023 | 100 | 3,069 (0%) | 0% | 18.5 | 1,850 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 18.49 per share. | 24 May 2023 | 100 | 2,969 (0%) | 0% | 18.5 | 1,849 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 18.19 per share. | 22 May 2023 | 100 | 2,869 (0%) | 0% | 18.2 | 1,819 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.53 per share. | 19 May 2023 | 100 | 3,369 (0%) | 0% | 16.5 | 1,653 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 16.70 per share. | 19 May 2023 | 100 | 2,869 (0%) | 0% | 16.7 | 1,670 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 17.12 per share. | 19 May 2023 | 100 | 3,269 (0%) | 0% | 17.1 | 1,712 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Grant, award, or other acquisition of securities at price $ 17.20 per share. | 04 May 2023 | 990 | 2,769 (0%) | 0% | 17.2 | 17,028 | Common Stock |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 25.78 per share. | 10 Feb 2023 | 387 | 1,779 (0%) | 0% | 25.8 | 9,975 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 01 Feb 2023 | 45,879 | 99,231 | - | 1.2 | 56,890 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.36 per share. | 01 Feb 2023 | 45,879 | 53,352 | - | 24.4 | 1,117,741 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 45,879 | 1,100,236 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.26 per share. | 01 Feb 2023 | 3,221 | 53,352 | - | 24.3 | 78,141 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 01 Feb 2023 | 3,221 | 56,573 | - | 1.2 | 3,994 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 3,221 | 1,097,015 | - | - | Stock Option (Right to | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 01 Feb 2023 | 900 | 54,252 | - | 1.2 | 1,116 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.27 per share. | 01 Feb 2023 | 900 | 53,352 | - | 24.3 | 21,844 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 900 | 1,146,115 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 50,000 | 53,352 | - | 0 | Common Stock | |
| OmniAb Inc | Sarah Boyce | Director | 01 Nov 2022 | 39,628 | 48,381 | - | - | Common Stock | ||
| Ligand Pharmaceuticals, In... | Sarah Boyce | Former Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 4,340 | 0 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Sarah Boyce | Former Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 1,004 | 2,892 (0%) | 0% | - | Common Stock | |
| Old Point Financial Corp. | Sarah Boyce Golden | Director | Purchase of securities on an exchange or from another person at price $ 24.22 per share. | 09 Sep 2022 | 41 | 1,385 (0%) | 0% | 24.2 | 993 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges